Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Diagnosis & Disease Information
Revised Policy Set to Improve Kidney Transplant Waitlist Time for Black Candidates
The OPTN policy revision may increase some Black kidney candidates’ total waiting time, which is a major factor in their transplant priority for organ offers.
Hepatitis C Guideline Updated for Chronic Kidney Disease Population
The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.
Resistant Hypertension Effectively Treated With Novel Drug
Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators.
It Is Time for Nephrology Practices to Bolster Their Nutrition Care
Practices need to look at all opportunities for preserving kidney function, according to the director of the Kidney Nutrition Institute.
Apixaban Tied to Lower Risk of Gastrointestinal Bleeding
Findings were consistent for patients aged 80 years or older and patients with chronic kidney disease, who are often underrepresented in clinical trials.
FDA Panel Votes on Tenapanor for Hyperphosphatemia in CKD
For patients who tolerated and remained on therapy, the average treatment effect on serum phosphorus was about -0.7mg/dL.
Kidney Function Declines More Slowly With SGLT2 Inhibitor
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
Empagliflozin Cuts Risk of Kidney Disease Progression, CV Death in CKD Patients
The EMPA-KIDNEY trial enrolled more than 6600 patients 18 years of age and older with CKD at risk of kidney disease progression.
Anemia Increases Dementia Risk in CKD
The association is revealed in a study of more 444,000 US veterans with new-onset chronic kidney disease.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...